Maltose octahexadecanoate | 445381-88-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 糖脂
• 英文名称: Maltose octahexadecanoate
• 英文别名: palmitoyl(-2)[palmitoyl(-3)][palmitoyl(-4)][palmitoyl(-6)]Glc(a1-4)[palmitoyl(-2)][palmitoyl(-3)][palmitoyl(-6)]Glc(b)-O-palmitoyl；[(2R,3R,4S,5R,6S)-4,5,6-tri(hexadecanoyloxy)-3-[(2R,3R,4S,5R,6R)-3,4,5-tri(hexadecanoyloxy)-6-(hexadecanoyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl hexadecanoate
• CAS: 445381-88-4
• 化学式: C₁₄₀H₂₆₂O₁₉
• 分子量: 2249.61
• InChiKey: WPLLISJGYIDIBU-DDSWDBSUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  57.9
• 重原子数：
  159
• 可旋转键数：
  132
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  238
• 氢给体数：
  0
• 氢受体数：
  19

文献信息

• Cosmetic compositions
  申请人：Unilever Home & Personal Care USA, Division of Conopco, Inc.

  公开号：US20020076386A1

  公开（公告）日：2002-06-20

  A cosmetic composition, preferably an antiperspirant composition, in solid or soft-solid form has a continuous phase which contains a water-immiscible liquid carrier and also contains a structurant which is partially or fully esterified maltose of the formulae: 1 which is the &bgr;-anomer, and optionally 2 which is the &agr;-anomer; wherein each Z is independently hydrogen or an acyl group of the formula: 3 where R denotes a hydrocarbyl group containing from 8 to 31 carbon atoms, with the proviso that not more than half of the Z groups are hydrogen, and the ratio of &bgr;-anomer to &agr;-anomer is from 65:35 to 100:0.

  一种固态或软固态的化妆品组合物，最好是止汗剂组合物，其连续相含有一种不溶于水的液体载体，还含有一种结构剂，这种结构剂是部分或全部酯化的配方中的麦芽糖： 1 是&bgr;-异构体，可选的还有 2 为&agr;-异构体； 其中每个 Z 独立地为氢或式中的酰基： 3 其中 R 表示含有 8 至 31 个碳原子的烃基，但 Z 基团中氢不超过一半，且 &bgr;-异构体与 &agr;-异构体的比例为 65:35 至 100:0。
• US6589515B2
  申请人：——

  公开号：US6589515B2

  公开（公告）日：2003-07-08
• [EN] ANTISENSE MODULATION OF STATI EXPRESSION<br/>[FR] MODULATION ANTI-SENS DE L'EXPRESSION DE STAT1
  申请人：ISIS PHARMACEUTICALS INC

  公开号：WO2003106713A1

  公开（公告）日：2003-12-24

  Antisense compounds, compositions and methods are provided for modulating the expression of STAT1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding STAT1. Methods of using these compounds for modulation of STAT1 expression and for treatment of diseases associated with expression of STAT1 are provided.